Medical marijuana companies need to gain the know-how seed banks have in order to develop new products. To that end, Dinafem has been working on R&D projects in an effort to launch better quality and more stable genetics that truly meet the needs of the medical cannabis industry.
In 1981, Dr. Raphael Mechoulam discovered the endocannabinoid system, consisting of CB1 receptors located in the brain and CB2receptors found in the immune system. This discovery provided new insights into medical cannabis and convinced the scientific community that cannabinoids found in cannabis plants activate and stimulate those receptors, provoking a natural reaction to pain, anxiety and stress.
D9-THC and CBD
There are two major cannabinoids that stimulate the aforementioned receptors: D9-THC (delta-9 tetrahydrocannabinol) and CBD (cannabidiol). THC is certainly the most famous and psychoactive component. However, CBD has been gaining the interest of the scientific and pharmaceutical community, owing to its multiple healing virtues.
CBD is one of more than 60 compounds found in the chemical phenotype of cannabis plants. Among its many functions, it has proved to be a natural protector against the psychoactive effects of THC. Evidence showing that CBD is far more effective than conventional therapy in treating child epilepsy has brought about the attention and interest of many pharmaceutical companies.
In addition, a review published in the British Journal of Clinical Pharmacology shows CBD to be a potent anti-inflammatory and analgesic capable of combating cancer cells and reducing nausea. No wonder its possible uses in the field of oncology are being investigated by people all over the world.
Back in the day, most cannabis strains on the market contained a much higher amount of THC than CBD. This was probably because most breeders preferred the psychoactive effect that THC-rich strains offered. Nevertheless, thanks to the recent discoveries regarding the medical benefits of CBD, this compound is becoming increasingly more appreciated. As seedbanks devote their time and effort to investigating and developing new cannabis genetics, pharmaceutical companies are seeing how beneficial CBD can be.
While THC might cause some undesired side effects when being used for medical purposes, there seems to be no apparent reason for thinking CBD presents the same problem. As evidence supporting the many therapeutic benefits of cannabidiol grows, pharmaceutical companies are starting to invest in research to obtain in-depth knowledge regarding the different ways CBD can be used in the medical field.
To that end, Supreme Pharmaceuticals in Canada has signed a partnership agreement with Dinafem, a world-renowned Spanish seedbank founded in 2002. Among many other things, it is known for being the first seed bank to market feminized autoflowering strains. As a result of this alliance, Supreme will gain from Dinafem’s know-how. The aim of this innovative partnership is to produce medical cannabis strains that could help patients authorized by the Marihuana for Medical Purposes Regulations (MMPR) in Canada.
“We are excited Supreme will be utilizing our genetics in their hybrid greenhouse,” states Mr. Gorospe, CEO of Dinafem. “Supreme’s commitment to producing high-quality, sun-grown cannabis is aligned with our own commitment to producing the best genetics. Dinafem is focused on market leading innovation in cannabis genetics, striving to maximize the potential of each variety,” he continues. “We look forward to working with Supreme to introduce our genetics to the Canadian market.”
Thanks to the time and money invested in a wide range of R&D projects, Dinafem has been able to make the most of its human and technological resources to develop cannabidiol-rich genetics that, according to the seedbank’s laboratory manager, are the result of a meticulous research process intended to satisfy the needs of medical and recreational cannabis users. “We have used selecting breeding techniques to create strains with high rates of CBD and lower THC content,” he says. “Through a meticulous selection process, only those genetics with the highest CBD content were chosen. By analyzing the plants’ chemical phenotype with a gas chromatograph, we could identify the number of cannabinoids found in each of them, after which our laboratory team managed to select those plants that presented a higher rate of CBD and were worthy of belonging to our elite line.”
Once the pure line took shape, Dinafem crossed those CBD-rich elite plants with world-renowned strains and obtained a wide range of hybrids that now make up its new catalogue of high-CBD strains.
Among the many genetics that harmoniously blend the traits such as flavour, aroma, strength and yield, of their predecessors in with the benefits of CBD, the ones worth a special mention are Amnesia CBD, Bubba Kush CBD and Cheese CBD. These are strains that, thanks to their 1:1, 1:2 and 1:3 THC/CBD ratio, are not only are ideal for therapeutic use, but also offer a far more sustainable alternative to patients who want to consume regularly without worrying about having their daily lives disrupted.
With this recent partnership, Supreme will now be able to investigate and develop strains with high medicinal value, while Dinafem will have access to a wide variety of R&D and cutting-edge techniques as well as information about the yield these strains possess when being cultivated in the remarkably big premises (350,000 sq. ft.) of Supreme. And, on top of that, the experience shared by thousands of medical users that avail themselves of those therapeutic strains will enable Dinafem to never stop looking for ways to improve.